Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

David G. Maloney, MD PhD, John Kuruvilla, MD, Christopher P Fox, MD PhD, Guillaume Cartron, MD PhD, Daniel Li, PhD, Jens Hasskarl, MD, Ashley Bonner, PhD, Yixie Zhang, PhD, Fei Fei Liu, BSc, MBA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137719

Published: 2020

Journal Articles

Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Tanya Siddiqi, MD, Ulrich Jaeger, MD, Olga Moshkovich, MPH, Jennifer Devlen, PhD, Matthew Miera, BSc, Agnes Williams, MSc, Jens Hasskarl, MD, Fei Fei Liu, BSc, MBA, Julia Braverman, PhD, Gilles Salles, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137656

Published: 2020

Journal Articles

The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)

Georg Lenz, Sarah C. Rutherford, Andrew Davies, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Jens Hasskarl, Sandra Margunato-Debay, Filipe Rodrigues, Lisette Nientker, Janita Balradj, Cathelijne Alleman

Blood (2018) 132 (Supplement 1): 2241.

https://doi.org/10.1182/blood-2018-99-112878

Published: 2018

Journal Articles

Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Elise A. Chong, MD, Nicole Winchell, Daniel J. Landsburg, MD, David L. Porter, MD, Anthony R. Mato, MD, Honore T Strauser, April M. Schrank-Hacker, Mariusz A Wasik, MD, Simon Francis Lacey, PhD BS, Jan Joseph Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD

Blood (2016) 128 (22): 3026.

https://doi.org/10.1182/blood.V128.22.3026.3026

Published: 2016

Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Nicole Winchell, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Simon F. Lacey, PhD, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2016) 128 (22): 1100.

https://doi.org/10.1182/blood.V128.22.1100.1100

Published: 2016

Journal Articles

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Simon F. Lacey, PhD BS, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Gaurav D. Shah, MD, Mariusz A. Wasik, MD, Katherine T. Marcucci, PhD, Zhaohui Zheng, MS, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2015) 126 (23): 183.

https://doi.org/10.1182/blood.V126.23.183.183

Published: 2015

Journal Articles

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Blood (2014) 124 (21): 3087.

https://doi.org/10.1182/blood.V124.21.3087.3087

Published: 2014

Journal Articles

Acute Panmyelosis with Myelofibrosis: Clinicopathological and Molecular Features of a Rare Malignant Bone Marrow Disease.

Silke Kapp-Schwoerer, Renate Looser, Franz Schaub, Michael Hummel, Manfred Olschewski, Jens Hasskarl, Michael Lübbert, MD, PhD, Ulrich Germing, Radek C. Skoda, MD, Annette H Schmitt-Graeff

Blood (2009) 114 (22): 3101.

https://doi.org/10.1182/blood.V114.22.3101.3101

Published: 2009

NARROW

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

The Burden of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Systematic Literature Review (SLR)

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Acute Panmyelosis with Myelofibrosis: Clinicopathological and Molecular Features of a Rare Malignant Bone Marrow Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only